Day One Biopharma updates Code of Ethics; no waivers granted

Day One Biopharmaceuticals, Inc.

Amendments cover conflicts of interest, related party transactions, confidentiality, and reporting violations.
Added provisions on fair dealing and compliance with healthcare laws.
No explicit or implicit waivers resulted from the amendments.
Code applies to all officers, directors, and employees.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Day One Biopharmaceuticals, Inc.: Amended Code of Business Conduct and Ethics to update policies on conflicts of interest, related party transactions, confidentiality, reporting violations, fair dealing, and healthcare law compliance (effective 2023-12-07).

Change: code of ethics
Effective: 2023-12-07

Exact text from the filing

On December 7, 2023, the Board of Directors (the “Board”) of Day One Biopharmaceuticals, Inc. (the “Company”) approved certain amendments to its Code of Business Conduct and Ethics

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-23-291669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.